Navigation Links
Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)

SEATTLE, Sept. 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.

"PIPs were introduced by the European Commission to help ensure that medicines that may have benefit in pediatric indications are evaluated in children," said Jack Singer, CTI's Chief Medical Officer. "Anthracyclines are a mainstay in the treatment of childhood leukemias, lymphomas and solid tumors but long-term cardiotoxicity represents a significant issue. We are planning to evaluate safety and efficacy of pixantrone in pediatric cancer patients."

CTI recently received a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010 in the U.S. regarding CTI's New Drug Application (NDA) for pixantrone as potential treatment for relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL).

About Pixantrone

Pixantrone (BBR 2778), is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class. Pixantrone has been granted fast track status.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

Sign up for email alerts and get RSS feeds at our Web site,

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective (including the failure to achieve the overall response rate, complete remissions and progression-free survival and the possibility of significant grade 3/4 adverse events, including cardiac disorders) for the treatment of relapsed or refractory aggressive NHL as determined by the FDA, and the potential failure of pixantrone to be approved by the EMEA (whether for a pediatric population or any other population) and that a decision by the FDA is not rendered by April 23, 2010, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200

    Investors Contact:
    Ed Bell
    T: 206.282.7100
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434

    Medical Information Contact:
    T: 800.715.0944

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split
3. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw Healthcare Conference
4. Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich
5. Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants
6. Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
7. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
8. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
9. Cell Therapeutics, Inc. Announces Exercise of Overallotment
10. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
11. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015  HUYA Bioscience International, ... China,s pharmaceutical innovations, today announced it has ... Development Fund (KDDF) to foster collaboration between KDDF and ... and commercialization of healthcare products for the global market. ... an important source of new innovative preclinical and clinical ...
(Date:11/30/2015)... San Jose, CA (PRWEB) , ... ... ... the Content Intelligence Company, today announced tighter software integration with MarkLogic, the ... management where organizations maximize information to drive change. , Smartlogic’s Content Intelligence ...
(Date:11/27/2015)... India , November 27, 2015 /PRNewswire/ ... --> Growing popularity of companion diagnostics ... in cancer biomarkers market with pharmaceutical companies ... in-demand companion diagnostic tests. ... --> Complete report on global cancer ...
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 Paris ... 2015.   --> Paris from 17 ... DERMALOG, the biometrics innovation leader, has invented the first ... fingerprints on the same scanning surface. Until now two different ... Now one scanner can capture both on the same ...
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/10/2015)... About signature verification Signature ... identify and verify the identity of an individual ... secure and accurate method of authentication and is ... because each individual,s signature is highly unique. Signature ... signature of an individual is compared and matched ...
Breaking Biology News(10 mins):